Mengkun Zhang

2.2k total citations · 1 hit paper
24 papers, 1.8k citations indexed

About

Mengkun Zhang is a scholar working on Cell Biology, Oncology and Molecular Biology. According to data from OpenAlex, Mengkun Zhang has authored 24 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cell Biology, 12 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Mengkun Zhang's work include Microtubule and mitosis dynamics (14 papers), Cancer-related Molecular Pathways (7 papers) and Inflammatory mediators and NSAID effects (4 papers). Mengkun Zhang is often cited by papers focused on Microtubule and mitosis dynamics (14 papers), Cancer-related Molecular Pathways (7 papers) and Inflammatory mediators and NSAID effects (4 papers). Mengkun Zhang collaborates with scholars based in United States, Canada and Japan. Mengkun Zhang's co-authors include Jean‐Pierre Pelletier, John A. Di Battista, Johanne Martel‐Pelletier, Yulan He, François Mineau, Dragan Jovanović, Jessica J. Huck, Mark Manfredi, Kara M. Hoar and Jeffrey Ecsedy and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Mengkun Zhang

23 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IL-17 Stimulates the Production and Expression of Proinflammatory Cytokines, IL-β and TNF-α, by Human Macrophages

1998 774 citations Dragan Jovanović, John A. Di Battista et al. The Journal of Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mengkun Zhang United States	13	728	681	677	524	172	24	1.8k
Scott Wardwell United States	15	1.6k 2.1×	222 0.3×	386 0.6×	644 1.2×	132 0.8×	22	2.4k
William F. Glass United States	23	768 1.1×	193 0.3×	386 0.6×	383 0.7×	68 0.4×	63	2.0k
Loretta Tuosto Italy	30	850 1.2×	195 0.3×	447 0.7×	1.7k 3.3×	117 0.7×	66	2.7k
Leslie A. Goldstein United States	23	1.5k 2.0×	539 0.8×	688 1.0×	502 1.0×	44 0.3×	26	2.6k
Michiko Niwa‐Kawakita France	22	1.5k 2.0×	428 0.6×	599 0.9×	201 0.4×	114 0.7×	31	2.9k
Praveen Bhoopathi United States	27	964 1.3×	204 0.3×	628 0.9×	403 0.8×	108 0.6×	52	1.9k
K R Auger United States	16	1.5k 2.0×	389 0.6×	511 0.8×	879 1.7×	63 0.4×	22	2.7k
Sandrine Marchetti France	24	1.2k 1.7×	239 0.4×	336 0.5×	354 0.7×	41 0.2×	42	2.1k
Christian Touriol France	30	1.8k 2.4×	314 0.5×	424 0.6×	228 0.4×	54 0.3×	46	2.5k
Norma Howells Germany	13	1.0k 1.4×	386 0.6×	321 0.5×	435 0.8×	49 0.3×	13	1.8k

Countries citing papers authored by Mengkun Zhang

Since Specialization

Citations

This map shows the geographic impact of Mengkun Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mengkun Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mengkun Zhang more than expected).

Fields of papers citing papers by Mengkun Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mengkun Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mengkun Zhang. The network helps show where Mengkun Zhang may publish in the future.

Co-authorship network of co-authors of Mengkun Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Mengkun Zhang. A scholar is included among the top collaborators of Mengkun Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mengkun Zhang. Mengkun Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yu, Jie, Jessica J. Huck, Matthew Theisen, et al.. (2016). Anti-tumor activity of TAK-659, a dual inhibitor of SYK and FLT-3 kinases, in AML models.. Journal of Clinical Oncology. 34(15_suppl). e14091–e14091. 6 indexed citations

Sells, Todd B., Ryan Chau, Jeffrey Ecsedy, et al.. (2015). MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors. ACS Medicinal Chemistry Letters. 6(6). 630–634. 83 indexed citations

Huck, Jessica J., Mengkun Zhang, Jerome T. Mettetal, et al.. (2014). Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib). Molecular Cancer Therapeutics. 13(9). 2170–2183. 27 indexed citations

Yang, Johnny, L. Yu, Arijit Chakravarty, et al.. (2014). Preclinical Drug Metabolism and Pharmacokinetics, and Prediction of Human Pharmacokinetics and Efficacious Dose of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237). Drug Metabolism Letters. 7(2). 96–104. 16 indexed citations

Huck, Jessica J., Rachael Brake, Helen He, et al.. (2014). Antitumor activity of inhibiting SYK kinase with TAK-659, an investigational agent, in DLBCL models.. Journal of Clinical Oncology. 32(15_suppl). 8580–8580. 4 indexed citations

Palani, Santhosh, Jessica J. Huck, Mengkun Zhang, et al.. (2013). Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. Cancer Chemotherapy and Pharmacology. 72(6). 1255–1264. 19 indexed citations

Ecsedy, Jeffrey, Xiaofei Zhou, Mengkun Zhang, et al.. (2013). Abstract 1169: Rational dose and schedule selection for the combination of paclitaxel and the investigational agent alisertib in recurrent ovarian cancer: optimization of therapeutic index based on translational hematological toxicity and exposure-efficacy modeling.. Cancer Research. 73(8_Supplement). 1169–1169. 1 indexed citations

Kelly, Kevin R., Steffan T. Nawrocki, Claudia M. Espitia, et al.. (2012). Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO‐dependent mechanism. International Journal of Cancer. 131(11). 2693–2703. 44 indexed citations

Manfredi, Mark, Jeffrey Ecsedy, Arijit Chakravarty, et al.. (2011). Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays. Clinical Cancer Research. 17(24). 7614–7624. 242 indexed citations

10.

Huck, Jessica J., Mengkun Zhang, Alice McDonald, et al.. (2010). MLN8054, an Inhibitor of Aurora A Kinase, Induces Senescence in Human Tumor Cells Both In vitro and In vivo. Molecular Cancer Research. 8(3). 373–384. 103 indexed citations

11.

Sells, Todd B., Jeffrey Ecsedy, Stephen G. Stroud, et al.. (2008). MLN8237: an orally active small molecule inhibitor of Aurora A kinase in phase I clinical trials. Cancer Research. 68. 237–237. 14 indexed citations

12.

Huck, Jessica J., Mengkun Zhang, Marc L. Hyer, & Mark Manfredi. (2008). Anti-Tumor Activity of the Aurora a Inhibitor MLN8237 in Diffuse Large B-Cell Lymphoma Preclinical Models.. Blood. 112(11). 1592–1592. 6 indexed citations

13.

Huck, Jessica J., Arijit Chakravarty, Yu Li, et al.. (2007). Preclinical PK/PD/Efficacy relationship of MLN8054, a small molecule Aurora A kinase inhibitor. Molecular Cancer Therapeutics. 6. 2 indexed citations

14.

Manfredi, Mark, Jeffrey Ecsedy, Kristan Meetze, et al.. (2007). Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proceedings of the National Academy of Sciences. 104(10). 4106–4111. 334 indexed citations

15.

Huck, Jessica J., Mengkun Zhang, Olga Burenkova, et al.. (2006). Preclinical antitumor activity with MLN8054, a small molecule Aurora A kinase inhibitor. Cancer Research. 66. 1104–1104. 8 indexed citations

16.

Manfredi, Mark, Jeffrey Ecsedy, Kristan Meetze, et al.. (2006). MLN8054, an orally active Aurora A kinase small molecule inhibitor in phase I clinical trials. Cancer Research. 66. 1110–1110. 5 indexed citations

17.

Zhang, Mengkun, Caroline Miller, Yulan He, et al.. (2000). Calphostin C induces AP1 synthesis and AP1-dependent c-jun transactivation in normal human chondrocytes independent of protein kinase c-? inhibition: Possible role for c-jun N-terminal kinase. Journal of Cellular Biochemistry. 76(2). 290–302. 15 indexed citations

18.

Battista, John A. Di, Mengkun Zhang, Johanne Martel‐Pelletier, et al.. (1999). Enhancement of phosphorylation and transcriptional activity of the glucocorticoid receptor in human synovial fibroblasts by nimesulide, a preferential cyclooxygenase 2 inhibitor. Arthritis & Rheumatism. 42(1). 157–166. 23 indexed citations

19.

Jovanović, Dragan, John A. Di Battista, Johanne Martel‐Pelletier, et al.. (1998). IL-17 Stimulates the Production and Expression of Proinflammatory Cytokines, IL-β and TNF-α, by Human Macrophages. The Journal of Immunology. 160(7). 3513–3521. 774 indexed citations breakdown →

20.

Miller, Caroline, Mengkun Zhang, Yulan He, et al.. (1998). Transcriptional induction of cyclooxygenase-2 gene by okadaic acid inhibition of phosphatase activity in human chondrocytes: Co-stimulation of AP-1 and CRE nuclear binding proteins. Journal of Cellular Biochemistry. 69(4). 392–413. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact